Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05963698 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Fourth Left Atrial Appendage Occlusion Study

Study acronym: LAAOS-4
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 140 → 150 locations
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 2 of 6 entries
    • Publications: details revised at 1 of 1 entry
  2. Trial sites expanded: 127 → 140 locationsv15
  3. Study sites: 108 to 127v14
  4. Study sites: 88 to 108v13
  5. Study sites: 64 to 88v12
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 53 to 64v11
  2. Study sites: 50 to 53v10
  3. Study sites: 31 to 50v9
  4. Study sites: 24 to 31v8
  5. Study sites: 22 to 24v7
  6. Study sites: 16 to 22v6
  7. Study sites: 2 to 16v5
  8. Study sites: 1 to 2v4
  9. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 1, 2023 to Nov 30, 2023
    v3
  10. Start date: Sep 1, 2023 to Nov 1, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Trial Details
NCT Number NCT05963698
Lead Sponsor Hamilton Health Sciences Corporation
Collaborators: McMaster University, Population Health Research Institute, Boston Scientific Corporation
Conditions
(from sponsor)		 Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Related terms Atrial Fibrillation, Ischemic Stroke
Enrollment 4,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov